Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-608 (napabucasin) plus weekly paclitaxel vs paclitaxel in previously treated non-squamous NSCLC
2016-002718-32Phase 3Active
- Sponsor
- Boston Biomedical
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of napabucasin in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Boston Biomedical. Primary endpoint: Overall Survival. Started Feb 2017; status: active.
02
Drugs
napabucasin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2016-002718-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002718-32.